Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CV Sciences, Inc. reported revenue of $14M, down 12.2% year over year. Operating margin was -3.4% and net margin -6.9%, on a free-cash-flow margin of -3.7% with capital expenditure at 0.8% of revenue. Every figure is computed directly from CVSI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $14M | -3.4% | -6.9% |
| FY2024 | $16M | -13.9% | -15.2% |
| FY2023 | $16M | 21.0% | 19.4% |
| FY2022 | $16M | -42.3% | -50.7% |
| FY2021 | $20M | -92.0% | -77.6% |
How does CVSI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.